Moderna, Inc.

MRNA · Nasdaq · SIC 2836: Biological Products, (No Diagnostic Substances) · Market Cap: $19.3B · 4,700 employees
86
SEC Filings
$50.96
Close 2026-04-10
7
Transcripts
4,700
Employees

Business Summary

Moderna is a biotechnology company and pioneer in mRNA medicine, focused on developing vaccines and therapeutics across infectious disease, oncology, and rare disease. The company currently markets three commercial products: Spikevax and mNEXSPIKE (COVID-19 vaccines) and mRESVIA (RSV vaccine). In 2025, Moderna generated $1.9 billion in total revenue, primarily from COVID vaccine sales, while advancing a broader pipeline including individualized cancer therapies.

Latest Stock Quote

MRNA 2026-04-10 $50.96 O:$51.67 H:$52.89 L:$50.02 Vol:6.3M VWAP:$51.625
origin leaf: b1e709586540cde70f4f0fb352778d63c233ba4647fcf044108e55bdbdc7ff7c

Next Earnings

Q2 FY2026 — expected 2026-07-24

Key Facts from Earnings Calls

TypeSubjectDetailQuarter
topic_mentionMRNAdiscussed Blockchain & Crypto
topic_mentionMRNAdiscussed Regulation
topic_mentionMRNAdiscussed Automotive
topic_mentionMRNAdiscussed Healthcare & Bio
topic_mentionMRNAdiscussed Capital Expenditure
topic_mentionMRNAdiscussed Supply Chain
topic_mentionMRNAdiscussed Regulation
topic_mentionMRNAdiscussed Automotive
topic_mentionMRNAdiscussed Healthcare & Bio
topic_mentionMRNAdiscussed Platform & Ecosystem
guidanceMRNAguided expect total revenue in 2025 to be in the range of $1.5 billion
guidanceMRNAguided expected to be approximately $1.1 billion
guidanceMRNAguided expect taxes to be negligible in 2025, and capital expenditures are projected to be approximately $400 million
guidanceMRNAguided expect to end 2025 with approximately $6 billion
guidanceMRNAguided forecast from $5.9 billion
guidanceMRNAguided guidance includes $0.9 billion
outlookMRNAstated We expect taxes to be negligible in 2025, and capital expenditures are projected to be approximately $400 million
outlookMRNAstated we expect to complete now by this summer
outlookMRNAstated We expect to have more clarity on the pace of case accrual and potential readout timing later this year
outlookMRNAstated We expect the potential for approval for M&A in 2028

Annual Reports (10-K)

FiledPeriodAccessionSourceFull Text
2026-02-202025-12-310001682852-26-000033EDGAR95K words
2025-02-212024-12-310001682852-25-000022EDGAR—
2024-02-232023-12-310001682852-24-000015EDGAR—
2023-02-242022-12-310001682852-23-000011EDGAR—
2022-02-252021-12-310001682852-22-000012EDGAR—
2021-02-262020-12-310001682852-21-000006EDGAR—

Quarterly Reports (10-Q)

FiledPeriodAccessionSourceFull Text
2025-11-062025-09-300001682852-25-000075EDGAR22K words
2025-08-012025-06-300001682852-25-000044EDGAR—
2025-05-012025-03-310001682852-25-000034EDGAR—
2024-11-072024-09-300001682852-24-000060EDGAR—
2024-08-012024-06-300001682852-24-000046EDGAR—
2024-05-022024-03-310001682852-24-000027EDGAR—
2023-11-032023-09-300001682852-23-000042EDGAR—
2023-08-032023-06-300001682852-23-000027EDGAR—
2023-05-042023-03-310001682852-23-000021EDGAR—
2022-11-032022-09-300001682852-22-000051EDGAR—
2022-08-032022-06-300001682852-22-000042EDGAR—
2022-05-042022-03-310001682852-22-000025EDGAR—

Recent Current Reports (8-K)

FiledAccessionSourceFull Text
2026-03-050001682852-26-000047EDGAR1K words
2026-02-130001682852-26-000015EDGAR—
2026-02-110001682852-26-000012EDGAR—
2026-01-120001682852-26-000007EDGAR—
2026-01-050001682852-26-000003EDGAR—
2025-11-240001628280-25-053816EDGAR—
2025-11-200001628280-25-053318EDGAR—
2025-11-130001628280-25-052055EDGAR—
2025-11-060001682852-25-000073EDGAR—
2025-08-010001682852-25-000041EDGAR—

86 total filings indexed. 58 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR

Earnings Transcripts

Call DateQuarterTitle
— MRNA Earnings Call Transcript
— MRNA Earnings Call Transcript
— MRNA Earnings Call Transcript
— MRNA Earnings Call Transcript
— MRNA Earnings Call Transcript
—Q1 FY3025MRNA Q1 FY3025 Earnings Call Transcript
—Q4 FY2025MRNA Q4 FY2025 Earnings Call Transcript

Access full transcripts via API (JSON) — includes speakers, key metrics, competitive mentions, and origin provenance chain.

Sector Peers

FDMT — 4D Molecular Therapeutics, Inc. APTN — ADAPTIN BIO, INC. ADMA — ADMA BIOLOGICS, INC. AGEN — AGENUS INC AIM — AIM ImmunoTech Inc. AMGN — AMGEN INC AVXL — ANAVEX LIFE SCIENCES CORP. ABPO — Abpro Holdings, Inc.

Tags

infectious-disease-vaccines oncology-therapeutics rare-disease-therapeutics respiratory-vaccines individualized-cancer-therapy mrna-medicine-platform individualized-neoantigen-therapy

Company Identity

CIK0001682852
TickerMRNA
ExchangeNasdaq
SIC2836: Biological Products, (No Diagnostic Substances)
IncorporatedDE
Websitehttps://www.modernatx.com
Listed2018-12-07

Get More Data

This is the free public profile. For structured JSON with full provenance chain, use the API:

JSON Profile Stock Quote AI Readiness Report
Origin Provenance
page leaf: c2bb2217944426b0eef93836199e7a116212b43b5be364e57f11930e489aa844
parent: dfeb4f4b670ffd04562d0b292d4ae046c25ff0cb3fde7d8d87f2cde6c47e6c22
content hash: decc880593690b8b0acc8b6cd0f76002006b115a5b075c20138ecd56652722e4
signed: 2026-04-13T04:46:21.188Z
sources: 26 verified data leaves
chain: SEC.gov PEM → origin.rootz.global extraction → this page
verify: sha256(content_hash + parent + timestamp) = leaf